Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLC7A11 siRNA
- Development stage
- Preclinical
- Lead developer
- Seoul National University College of Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
SLC7A11 siRNA is a preclinical RNA interference (RNAi) therapeutic designed to silence the expression of the SLC7A11 gene, also known as xCT. SLC7A11 is a critical component of the cystine/glutamate antiporter system, which is frequently upregulated in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) to maintain redox homeostasis and promote chemoresistance. By specifically knocking down SLC7A11, this siRNA reduces the glutathione (GSH) pool, elevates oxidative stress (lipid ROS), and suppresses tumorigenic traits such as migration, invasion, and epithelial-mesenchymal transition (EMT). Furthermore, SLC7A11 silencing has been shown to downregulate SMAD signaling by reducing the stability of receptor-regulated SMADs (R-SMADs), effectively overcoming gemcitabine resistance in KRAS-driven pancreatic cancer models.
- Other names
- xCT siRNASLC7A11-targeting siRNASLC-7A11-targeting siRNASLC 7A11-targeting siRNA
02
Targets
SLC7A11 (Cystine-Glutamate Antiporter)
Beyond the preview
Go deeper on SLC7A11 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC7A11 siRNA.